3,687 results on '"Imidazoles adverse effects"'
Search Results
2. Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial.
- Author
-
Lee JH, Goh HJ, Lee K, Choi DW, Lee KM, and Kim S
- Subjects
- Humans, Male, Prospective Studies, Aged, Middle Aged, Urinary Bladder, Overactive drug therapy, Urinary Bladder, Overactive etiology, Recovery of Function, Postoperative Complications drug therapy, Treatment Outcome, Drug Administration Schedule, Cholinergic Antagonists therapeutic use, Cholinergic Antagonists administration & dosage, Cholinergic Antagonists adverse effects, Urological Agents therapeutic use, Urological Agents administration & dosage, Robotic Surgical Procedures adverse effects, Prostatectomy adverse effects, Prostatectomy methods, Imidazoles therapeutic use, Imidazoles administration & dosage, Imidazoles adverse effects, Urinary Incontinence etiology, Prostatic Neoplasms surgery
- Abstract
Purpose: This study aims to prospectively analyze the effects of anticholinergic therapy using imidafenacin on detrusor overactivity occurring after robot-assisted radical prostatectomy (RARP)., Materials and Methods: Patients were followed-up at outpatient visits 2-4 weeks post-surgery (visit 2) to confirm the presence of urinary incontinence. Those confirmed with urinary incontinence were randomly assigned in a 1:1 ratio to the anticholinergic medication group (imidafenacin 0.1 mg twice daily) or the control group. Patients were followed-up at 1, 3, and 6 months post-surgery for observational assessments, including the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS)., Results: A total of 49 patients (25 in the treatment group and 24 in the control group) were randomized for the study. There were no differences observed between the groups in terms of age, comorbidities, prostate size, or pathological staging. According to the IPSS questionnaire results, there was no statistically significant difference between the medication and control groups (p=0.161). However, when comparing storage and voiding symptoms separately, there was a statistically significant improvement in storage symptom scores (p=0.012). OABSS also revealed statistically significant improvement in symptoms from 3 months post-surgery (p=0.005), which persisted until 6 months post-surgery (IPSS storage: p=0.023, OABSS: p=0.013)., Conclusions: In the case of urinary incontinence that occurs after RARP, even if the function of the intrinsic sphincter is sufficiently preserved, if urinary incontinence persists due to changes in the bladder, pharmacological therapy using imidafenacin can be beneficial in managing urinary incontinence., Competing Interests: The authors have nothing to disclose., (© The Korean Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
3. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
- Author
-
Ueberroth BE, Lieu CH, and Lentz RW
- Subjects
- Humans, Male, Middle Aged, Liver Neoplasms secondary, Liver Neoplasms drug therapy, Liver Neoplasms genetics, Female, Neoplasm Grading, Treatment Outcome, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Imidazoles therapeutic use, Imidazoles administration & dosage, Imidazoles adverse effects, Oximes therapeutic use, Oximes administration & dosage, Proto-Oncogene Proteins B-raf genetics, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, Pyrimidinones therapeutic use, Pyrimidinones administration & dosage, Pyridones therapeutic use, Pyridones administration & dosage, Mutation, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors genetics, Neuroendocrine Tumors pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Purpose: Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3., Methods: This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue., Results: This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T., Conclusion: Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan.
- Author
-
Nakano E, Takahashi A, Ogata D, Namikawa K, and Yamazaki N
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Japan, Aged, Adult, Aged, 80 and over, Molecular Targeted Therapy, Mutation, Progression-Free Survival, Survival Rate, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Melanoma drug therapy, Melanoma mortality, Melanoma pathology, Melanoma genetics, Oximes administration & dosage, Oximes adverse effects, Pyrimidinones administration & dosage, Pyrimidinones adverse effects, Pyrimidinones therapeutic use, Pyridones administration & dosage, Pyridones adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzimidazoles administration & dosage, Benzimidazoles adverse effects, Imidazoles administration & dosage, Imidazoles adverse effects, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms mortality, Skin Neoplasms genetics, Carbamates administration & dosage, Carbamates adverse effects, Carbamates therapeutic use, Sulfonamides administration & dosage, Sulfonamides adverse effects
- Abstract
Most clinical trials investigating targeted therapies for patients harboring BRAF V600 mutations have included mostly White patients, and data for Asian patients are scarce. Although there are several retrospective studies in Japanese patients, they have investigated only the dabrafenib + trametinib regimen, and have had a short follow-up period. We conducted a single-center retrospective study to update previous studies and compare the outcomes with those in White patients. We analyzed 89 patients who received dabrafenib + trametinib or encorafenib + binimetinib, including 11 who received both treatment regimens. The overall response rate was 79.8%, with complete response in 25 patients (28.1%) and partial response in 45 patients (51.7%). The median progression-free survival was 13.7 months, and the median overall survival was 32.9 months. The 3-year progression-free and overall survival rates were 31.8% and 47.9%, respectively. Although the two regimens showed no significant differences in efficacy, their safety profiles differed, as reported in clinical trials. Therefore, the most frequent adverse event associated with the dabrafenib + trametinib regimen was pyrexia (61.3%) and that of encorafenib + binimetinib was blurred vision (32.0%). Switching directly to another targeted therapy after progressive disease showed no clinical response; however, rechallenge followed by immune checkpoint inhibitor therapy showed a certain response. As a prognostic factor, performance status was associated with progression-free survival, and performance status, serum lactate dehydrogenase level, and dose interruption were associated with overall survival in the multivariate analysis. Real-world data on targeted therapy for patients with melanoma in Japan suggest that both dabrafenib + trametinib and encorafenib + binimetinib show similar efficacy and safety in Asian and White patients., (© 2024 Japanese Dermatological Association.)
- Published
- 2024
- Full Text
- View/download PDF
5. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Author
-
Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, and Mei M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Aged, Maintenance Chemotherapy, Philadelphia Chromosome, Pyridazines therapeutic use, Pyridazines adverse effects, Pyridazines administration & dosage, Imatinib Mesylate therapeutic use, Imatinib Mesylate adverse effects, Imatinib Mesylate administration & dosage, Imidazoles adverse effects, Imidazoles administration & dosage, Imidazoles therapeutic use, Young Adult, Transplantation, Homologous, Adolescent, Tyrosine Kinase Inhibitors, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage
- Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post-HCT, but published clinical experience is primarily with the first-generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second-generation TKI (2G-TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty-six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G-TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G-TKI: 576.0 days (range, 72-921) versus 254.5 days (range, 3-2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5-year overall survival and progression-free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post-HCT TKI maintenance in a large real-world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
6. The Incidence and Severity of Medication Related Osteonecrosis of the Jaws is Similar in Male and Female Mice.
- Author
-
Hadaya D, Soundia A, Bezouglaia O, Pirih F, Aghaloo TL, and Tetradis S
- Subjects
- Animals, Female, Male, Mice, Sex Factors, Incidence, Periodontitis pathology, Disease Models, Animal, Alveolar Bone Loss diagnostic imaging, Zoledronic Acid therapeutic use, Zoledronic Acid adverse effects, Bisphosphonate-Associated Osteonecrosis of the Jaw pathology, Bisphosphonate-Associated Osteonecrosis of the Jaw diagnostic imaging, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Imidazoles adverse effects, Random Allocation
- Abstract
Background: Medication related osteonecrosis of the jaws (MRONJ), a rare side-effect of antiresorptive medications, is described as exposed bone in the oral cavity that lasts for at least 8 weeks. Most studies report a female predilection for MRONJ; these findings could be due to the increased use of antiresorptives in females, or due to inherent differences between male versus female patients., Purpose: The purpose of this study was to measure and compare the incidence and severity of osteonecrosis of the jaws (ONJ) between male and female mice., Study Design, Setting, Sample: We designed a randomized in-vivo animal study utilizing male and female mice treated with zoledronic acid (ZA). Experimental periodontitis was induced in 24 male and 24 female mice using a silk ligature following administration of saline or a potent bisphosphonate. After 8 weeks, animals were evaluated radiographically and histologically., Independent Variable: The independent variables were sex (male vs female) and treatment group (ZA vs saline control). Treatment was randomly assigned with balanced distribution between male and female animals., Main Outcome Variable: The main outcome variable was ONJ status coded as present or absent. ONJ was defined as present if there was histologic contact between the ligature and the alveolar bone. Secondary outcomes of interest were radiographic and histologic parameters., Analysis: Statistical differences were analyzed using a two-way analysis of variance with Tukey's post hoc test using a P value of 0.05 for significance., Results: The final sample was composed of 24 vehicle treated and 24 ZA treated animals. In vehicle treated animals, 8% of female and 8% of male animals developed ONJ. In ZA treated animals, 83% of female and 92% of male animals developed ONJ. Sex was not associated with the risk (measured as incidence of disease) for developing ONJ or in the radiographic or histologic parameters that were assessed (P values >.1)., Conclusions: Sex does not appear to affect the incidence of MRONJ or the severity of the disease as assessed by the radiographic and histologic parameters., (Copyright © 2024 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Severe sepsis induced by zoledronic acid: A case report.
- Author
-
Liao L and Zhang Z
- Subjects
- Humans, Female, Middle Aged, Osteoporosis drug therapy, Diphosphonates adverse effects, Diphosphonates therapeutic use, Imidazoles adverse effects, Zoledronic Acid adverse effects, Zoledronic Acid therapeutic use, Sepsis drug therapy, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents therapeutic use
- Abstract
Rationale: Zoledronic acid is one of the most commonly used intravenous, highly potent amino diphosphonate salts worldwide and is commonly used in patients with primary or secondary osteoporosis, most of whom are well tolerated. There are currently no reports of severe sepsis induced by zoledronic acid. Here we present the first case of severe sepsis induced by zoledronic acid. We reviewed the literature and found that there is currently a lack of reports on severe sepsis induced by zoledronic acid or other diphosphonates., Patient Concerns: A 58-year-old woman with severe osteoporosis and Behcet disease developed severe sepsis after treatment with zoledronic acid., Diagnosis: Sepsis, septic shock, acute kidney injury, intestinal infection, Behcet disease., Interventions: The patient was given intensive care immediately after admission, and massive fluid infusion to expand blood volume could not maintain normal blood pressure. Metaraminol was added to maintain circulatory stability, piperacillin-tazobactam was used to strengthen anti-infection, and glucocorticoids were used for anti-inflammatory treatment., Outcomes: The patient was discharged with improvement and followed up in the outpatient clinic., Lessons: The inducing mechanism of zoledronic acid is not clear, but when the patient has immunosuppression, the use of zoledronic acid should be cautious and monitored. In conclusion, severe sepsis induced by zoledronic acid is a rare but serious complication, and physicians should be aware of this adverse event in time to avoid serious consequences., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
8. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
- Author
-
Takahashi N, Kondo T, Ikari Y, Fukumoto Y, Hatake K, Masunari A, Nishibayashi S, Kageyama A, Fukuta Y, and Tojo A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Japan epidemiology, Adult, Aged, 80 and over, Young Adult, Adolescent, Treatment Outcome, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Imidazoles adverse effects, Imidazoles administration & dosage, Imidazoles therapeutic use, Pyridazines adverse effects, Pyridazines therapeutic use, Pyridazines administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Product Surveillance, Postmarketing, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Arterial Occlusive Diseases chemically induced, Arterial Occlusive Diseases epidemiology
- Abstract
Background: In September 2016, ponatinib was approved in Japan for the treatment of patients with chronic myeloid leukemia with resistance/intolerance to prior tyrosine kinase inhibitors and patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia., Methods: We conducted a post-marketing all-case surveillance to study the safety and efficacy of ponatinib in clinical practice, focusing on arterial occlusive events., Results: Data from 724 patients were collected for 2 years from the initiation of ponatinib. The arterial occlusive events were reported in 6.49% (47/724) with an exposure-adjusted incidence rate of 6.8/100 person-years. The risks associated with arterial occlusive events were age and comorbidities including hypertension and diabetes. At 104 weeks, the cumulative major molecular response rate in patients with chronic-phase chronic myeloid leukemia was 67.2% and the complete cytogenetic response in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia was 80.0%. Furthermore, the estimated 1-year overall survival rate was 98.5% for chronic-phase chronic myeloid leukemia and 68.6% for Philadelphia chromosome-positive acute lymphoblastic leukemia., Conclusions: This surveillance demonstrated that ponatinib has a favorable safety and efficacy profile in Japanese patients and also showed the necessity of closely monitoring arterial occlusive events in older adults and patients with predisposing factors for atherosclerosis., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
9. Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre, randomized and open-label controlled trial.
- Author
-
Wang H, Huang J, Tao L, Liu D, and Song C
- Subjects
- Humans, Female, Aged, Treatment Outcome, Middle Aged, Pain Measurement, Bone Density drug effects, Alendronate therapeutic use, Alendronate adverse effects, Alendronate administration & dosage, Osteoporosis, Postmenopausal drug therapy, Bone Density Conservation Agents therapeutic use, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents administration & dosage, Diphosphonates therapeutic use, Diphosphonates adverse effects, Diphosphonates administration & dosage, Randomized Controlled Trials as Topic, Low Back Pain drug therapy, Imidazoles therapeutic use, Imidazoles adverse effects, Imidazoles administration & dosage
- Abstract
Background: Low back pain is one of the most common symptoms of osteoporosis. The pain can seriously affect patients' mood and quality of life; it can also further aggravate bone loss, causing a serious social burden. Minodronate is an oral bisphosphonate that needs to be administered daily. It significantly reduces levels of bone turnover markers (BTMs) and rapidly improves symptoms of low back pain in patients with osteoporosis. Osteoporosis requires long-term treatment, and daily dosing reduces patient compliance. Minodronate has a better safety profile than other bisphosphonates. The objective of the trial is to explore the efficacy and safety of minodronate in the treatment of low back pain in postmenopausal osteoporosis patients., Methods: This is a single-centre, randomized, open-label controlled trial with a 24-week duration. Seventy-two eligible patients will be randomly divided into 4 groups. Subjects will be randomized at a 1:1 ratio to receive either minodronate (1 mg/day) or alendronate (10 mg/day) every day; senior women (≥ 75 years old) and older women (< 75 years old) will be at a ratio of 1:2. The primary outcome is the time required for the visual analogue scale (VAS) score to decline by ≥ 10 from baseline. The secondary outcome is the changes in VAS scores from baseline, the frequency and dosage of rescue medication, BTMs, bone mineral density (BMD), and variations in upper gastrointestinal (GI) symptom scores from baseline (including heartburn, pain, and bloating)., Discussion: This study will provide objective evidence for the efficiency and safety of minodronate. Furthermore, it will be helpful to evaluate the quantitative relationship between BTMs and BMD in patients with osteoporosis under different ages., Trial Registration: This study protocol has been registered with ClinicalTrials.gov ID NCT05645289 ( https://clinicaltrials.gov/search?term=NCT05645289 ) on December 8, 2022. The registry name is Peking University Third Hospital. This study protocol was reviewed and approved by the Peking University Third Hospital Medical Science Research Ethics Committee (M2022465, 2022.08.09, V2.0). The results will be published in scientific peer-reviewed journals., Trial Status: The protocol was registered at ClinicalTrials.gov (registration number: NCT05645289). Recruitment has started in January 2023 and is still ongoing., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study.
- Author
-
De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, Briet C, Almairac F, Boetto J, Mouly C, Larrieu-Ciron D, Vasiljevic A, Villa C, Sergeant C, Ducray F, Feuvret L, Chanson P, Baussart B, Raverot G, and Jouanneau E
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Retrospective Studies, Aged, Cohort Studies, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Molecular Targeted Therapy methods, Imidazoles therapeutic use, Imidazoles administration & dosage, Imidazoles adverse effects, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics, Craniopharyngioma drug therapy, Pyridones therapeutic use, Pyridones administration & dosage, Pyridones adverse effects, Pituitary Neoplasms drug therapy, Pyrimidinones therapeutic use, Pyrimidinones administration & dosage, Pyrimidinones adverse effects, Oximes therapeutic use, Oximes administration & dosage, Oximes adverse effects
- Abstract
Objective: Targeted therapy (TT) with BRAF/MEK inhibitors has emerged as a potential treatment in papillary craniopharyngiomas (PCPs). However, standardized data on large cohorts are lacking. Our study aimed to assess real-life efficacy and safety of BRAF/MEK inhibition in patients with PCPs., Design: Retrospective French multicenter study involving BRAF V600E-mutated PCP patients, treated with BRAF/MEK inhibitor combination dabrafenib and trametinib, from April 2019 to July 2023., Methods: Objective response and clinical and safety outcomes were assessed after 3 months and at the last available follow-up during TT., Results: Sixteen patients (8 females, mean age 50.5 ± 15.75 years), receiving either neoadjuvant therapy (NEO) for non-resectable tumors (n = 6), post-surgical adjuvant therapy (ADJ; n = 8), or palliative therapy (PAL) following failure of multimodal treatment (n = 2), were included.At the last follow-up (mean 7.6 ± 5.3 months), 12 patients showed subtotal response, 3 exhibited partial response, and 1 maintained stable disease. Mean volume reduction was 88.9 ± 4.4%, 73.3 ± 23.4%, and 91.8 ± 4.3% in the NEO, ADJ, and PAL groups, respectively.Targeted therapy resolved headaches in 5/5 patients and visual impairment in 6/9; 2/3 patients had improved neurological symptoms, 1/4 presented weight loss, and 2/14 recovered endocrine function.Targeted therapy was well-tolerated in 62.5% of cases; adverse events led to treatment discontinuation in 5 patients and definitive discontinuation in 3 cases., Conclusions: In this study, 94% of patients showed partial response or better to TT. Adverse events were acceptable. Further research is needed to establish standardized protocols; however, these results advocate for a NEO approach in invasive PCPs., Competing Interests: Conflict of interest: The authors have no relevant financial or nonfinancial interests to disclose. Co-author G.R. is on the editorial board of EJE. He was not involved in the review or editorial process for this paper, on which they are listed as authors., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
11. Neonatal Acute Kidney Injury due to Maternal Olmesartan Intake.
- Author
-
Saha AK, Padhi P, Hota D, and Rathore V
- Subjects
- Humans, Infant, Newborn, Female, Pregnancy, Antihypertensive Agents adverse effects, Male, Angiotensin II Type 1 Receptor Blockers adverse effects, Acute Kidney Injury chemically induced, Imidazoles adverse effects, Tetrazoles adverse effects
- Published
- 2024
- Full Text
- View/download PDF
12. Bone Augmentation With Alloplastic Graft Material in a Patient Under Bisphosphonate Therapy: A Case Report and Literature Review.
- Author
-
Narahara S, Ohba S, Ichinose S, Yamanouch Y, Kuroshima S, Shido R, Sawase T, and Yamada T
- Subjects
- Humans, Female, Aged, Tooth Socket surgery, Tooth Extraction, Imidazoles therapeutic use, Imidazoles adverse effects, Bone Substitutes therapeutic use, Mandible surgery, Osteoporosis drug therapy, Dental Implantation, Endosseous, Molar surgery, Alveolar Ridge Augmentation methods, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents therapeutic use, Diphosphonates adverse effects, Diphosphonates therapeutic use
- Abstract
Cases of relatively safe dental implant treatment in patients with low-volume bisphosphonate (BP) have been gradually reported. Although bone augmentation is commonly used when the bone volume is insufficient for implant placement, the studies and case reports regarding the safety of bone augmentation in patients treated with BP remain insufficient. Herein, we report a case wherein bone augmentation was performed after BP treatment with bone healing realized according to imaging, and we review the literature regarding BP and bone augmentation. A 67-year-old Japanese woman requested implant treatment for a hopeless lower right second molar. She had been taking minodronic acid hydrate (50 mg/4 wk) for 18 months to treat steroid-induced osteoporosis. After obtaining informed consent, tooth extraction and bone augmentation within the extraction socket were performed. The tooth was extracted atraumatically to preserve the surrounding alveolar bone, and the extraction socket was intensely curetted. Subsequently, the socket was filled with carbonate apatite granules and covered with a biodegradable membrane, and the wound was sutured without tension. Although protracted wound healing without any symptoms of infection was observed, the wound healed completely. No clinical symptoms were observed, the color of the mucosa at the site was healthy, and imaging findings at 6 months postoperation indicated that osteogenesis had progressed uneventfully.
- Published
- 2024
- Full Text
- View/download PDF
13. Cucurbit[7]uril-based host-guest complexes for improving bioavailability and reducing side effects of piroxicam.
- Author
-
Wang Y, Yang X, Luo J, Yi S, Guo T, Liao Y, Yu C, and Zhang X
- Subjects
- Animals, Male, Mice, Rats, Sprague-Dawley, Rats, Drug Liberation, Administration, Oral, Heterocyclic Compounds, 2-Ring, Macrocyclic Compounds, Imidazolidines, Piroxicam administration & dosage, Piroxicam chemistry, Piroxicam pharmacokinetics, Piroxicam adverse effects, Biological Availability, Imidazoles chemistry, Imidazoles administration & dosage, Imidazoles pharmacokinetics, Imidazoles adverse effects, Bridged-Ring Compounds chemistry, Bridged-Ring Compounds administration & dosage, Bridged-Ring Compounds pharmacokinetics, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal chemistry, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Anti-Inflammatory Agents, Non-Steroidal adverse effects, beta-Cyclodextrins chemistry, beta-Cyclodextrins administration & dosage, Solubility
- Abstract
Piroxicam (PX) is a nonsteroidal anti-inflammatory drug (NSAID) commonly associated with gastrointestinal (GI) injuries, including dyspepsia, heartburn, inflammation, bleeding, ulceration, and life-threatening perforation. The β-cyclodextrin (β-CD)-based PX formulation (PX@CD) has been shown to reduce gastric side effects by improving PX's solubility and dissolution rates. However, the solubility of PX can only be increased to a limited extent by β-CD, due to the low binding constant between PX and β-CD (∼100 M
-1 ). As a result, adverse reactions such as epigastric pain and pyrosis are still commonly reported. Cucurbit[7]uril (CB[7]) is a synthetic macrocyclic host compound that binds strongly to various drugs. In this study, we demonstrated that CB[7] forms complexes with PX in the gastric acid environment with a binding constant approximately 70 times higher than that between β-CD and PX. The PX@CB[7] inclusion complexes exhibited rapid dissolution rates in the gastric environment. In addition, PX@CB[7] showed significantly higher oral bioavailability and maximum concentration (Cmax ) compared to PX and PX@CD (1:2.5), resulting in improved anti-inflammatory effects in both mouse and rat models. Moreover, PX@CB[7] (1:2.5) had the least adhesion to the gastric mucosa and caused the mildest gastric side effects in rat models when compared to PX, PX@CD (1:2.5), and PX@CB[7] (1:1). Lastly, CB[7] demonstrated good oral biocompatibility in a subacute toxicity evaluation study. These findings indicate that CB[7] could be used as an excipient to improve treatment effectiveness and decrease adverse reactions in orally administered formulations with a favorable safety profile., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Xiangjun Zhang reports financial support was provided by Natural Science Foundation Project of Chongqing. Xiangjun Zhang reports financial support was provided by Chongqing Municipal Education Commission Foundation. Yan Wang, Chao Yu and Xiangjun Zhang has patent pending to National Intellectual Property Administration,PRC. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
14. Proximal Renal Tubular Acidosis Complicated by Severe Hypocalcemia Caused by Malnutrition and Inappropriate Long-term Use of Zoledronate: A Case Report and Review of the Literature.
- Author
-
Fujita N, Ono Y, Yamashita K, Kimata M, Sekizawa A, Hashimoto K, Obuchi Y, and Tanaka Y
- Subjects
- Humans, Male, Aged, 80 and over, Bone Density Conservation Agents adverse effects, Prostatic Neoplasms drug therapy, Prostatic Neoplasms complications, Hypocalcemia chemically induced, Zoledronic Acid adverse effects, Acidosis, Renal Tubular chemically induced, Imidazoles adverse effects, Malnutrition complications, Malnutrition chemically induced, Diphosphonates adverse effects
- Abstract
An 80-year-old man presented with electrolyte abnormalities, particularly hypocalcemia (3.6 mg/dL). He was diagnosed with bone and lymph node metastases from prostate cancer seven years earlier and continuously received goserelin, bicalutamide, and zoledronate. He later developed gradually worsening hypocalcemia, hypokalemia, hypophosphatemia, hypouricemia, renal dysfunction, and weight loss. Urinary potassium and phosphate loss, renal glucosuria, metabolic acidosis, and a low urine pH (5.0) were observed. Given the acquired onset and clinical course, we diagnosed the patient with zoledronate-induced proximal renal tubular acidosis. In the present case, severe hypocalcemia may have been caused by malnutrition and inappropriate long-term use of zoledronate.
- Published
- 2024
- Full Text
- View/download PDF
15. Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib
- Author
-
Geçgel A, Ön S, Çiftçi Y, Özkan O, Açar FP, and Karaca B
- Subjects
- Humans, Melanoma drug therapy, Female, Male, Middle Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Pyridones adverse effects, Pyridones therapeutic use, Pyrimidinones adverse effects, Pyrimidinones therapeutic use, Oximes adverse effects, Oximes therapeutic use, Imidazoles adverse effects, Imidazoles therapeutic use, Guillain-Barre Syndrome drug therapy
- Published
- 2024
- Full Text
- View/download PDF
16. Ponatinib superior to imatinib in Ph + ALL.
- Author
-
Sidaway P
- Subjects
- Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pyridazines therapeutic use, Pyridazines adverse effects, Imatinib Mesylate therapeutic use, Imidazoles therapeutic use, Imidazoles adverse effects
- Published
- 2024
- Full Text
- View/download PDF
17. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
- Author
-
Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, and Kantarjian H
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Pyridazines therapeutic use, Pyridazines adverse effects, Pyridazines administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Imidazoles therapeutic use, Imidazoles adverse effects, Imidazoles administration & dosage, Philadelphia Chromosome, Recurrence
- Published
- 2024
- Full Text
- View/download PDF
18. Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
- Author
-
Elmes JB, Davis JM, Musselwhite LW, Chiad Z, Moore DC, and Amin A
- Subjects
- Humans, Pharmacovigilance, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Male, Middle Aged, Female, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aged, Melanoma drug therapy, Imidazoles adverse effects, Imidazoles administration & dosage, Oximes adverse effects, Oximes administration & dosage, Oximes therapeutic use, Pyrimidinones adverse effects, Pyrimidinones administration & dosage, Pyridones adverse effects, Lymphohistiocytosis, Hemophagocytic chemically induced
- Abstract
Hemophagocytic lymphohistiocytosis (HLH) has been reported rarely with BRAF/MEK inhibitor combinations, including dabrafenib/trametinib. Postmarketing pharmacovigilance analyses evaluating outcomes associated with dabrafenib/trametinib-induced HLH are also lacking. Herein, we report a case of dabrafenib/trametinib-induced HLH in a patient with metastatic melanoma. Recovery of HLH-related symptoms was observed following drug discontinuation, supportive care, and corticosteroids. We also conducted a pharmacovigilance analysis of the USA Food and Drug Administration Adverse Event Reporting System (FAERS) to describe postmarketing cases of HLH with dabrafenib/trametinib exposure. There were 50 reports of HLH with dabrafenib/trametinib in FAERS. Most cases occurred in the setting of melanoma ( n = 39; 78%) and most were reported in Europe ( n = 39; 74%). Hospitalization was the most common outcome ( n = 39; 78%) of this adverse event per FAERS. HLH is a rare complication of dabrafenib/trametinib, and clinicians should be aware and monitor for signs of this potentially serious and life-threatening adverse event., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
- Author
-
Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, Cortes J, Nicolini FE, Issa GC, Jabbour E, and Kantarjian H
- Subjects
- Humans, Middle Aged, Adult, Male, Female, Aged, Young Adult, Follow-Up Studies, Leukemia, Myeloid, Chronic-Phase drug therapy, Fusion Proteins, bcr-abl genetics, Fusion Proteins, bcr-abl antagonists & inhibitors, Treatment Outcome, Dasatinib adverse effects, Dasatinib therapeutic use, Dasatinib administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Pyridazines adverse effects, Pyridazines therapeutic use, Pyridazines administration & dosage, Imidazoles adverse effects, Imidazoles therapeutic use, Imidazoles administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality
- Abstract
Background: Ponatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome-positive leukemias. Herein, we report the long-term follow-up of the phase 2 trial of ponatinib in chronic myeloid leukemia in chronic phase., Methods: Patients received ponatinib 30 to 45 mg/day. The primary end point was the rate of 6-month complete cytogenetic response (CCyR). The study was held in June 2014 because of the risk of cardiovascular toxicity, requiring patients to change TKI., Results: Fifty-one patients were treated with ponatinib (median dose, 45 mg/day). Median age was 48 years (range, 21-75); 30 (59%) had baseline cardiovascular comorbidities. Median treatment duration was 13 months (range, 2-25). Fourteen patients (28%) discontinued ponatinib because of toxicities, 36 (71%) after the Food and Drug Administration warning/study closure, and one for noncompliance. Dasatinib was the most frequently chosen second-line TKI (n = 34; 66%). Among 46 patients evaluable at 6 months, 44 (96%) achieved CCyR, 37 (80%) major molecular response, 28 (61%) MR4, and 21 (46%) MR4.5. The cumulative 6-month rates of CCyR, major molecular response, MR4, and MR4.5 were 96%, 78%, 50%, and 36%, respectively. Durable MR4 ≥24 or ≥60 months was observed in 67% and 51% of patients, respectively. The 24-month event-free survival rate was 97%. After a median follow-up of 128 months, the 10-year overall survival rate was 90%. Eight patients (16%) had serious grade 2 to 3 cardiovascular adverse events, leading to permanent discontinuation in five (10%)., Conclusion: Ponatinib yielded high cytogenetic and molecular responses in newly diagnosed chronic myeloid leukemia in chronic phase. Its use in the frontline setting is hindered by arterio-/vaso-occlusive and other severe toxicities., (© 2024 American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
20. Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System.
- Author
-
Zhou T, Chen C, Chen X, Wang B, Sun F, Li W, Liu D, and Jin H
- Subjects
- Female, Humans, United States, Pregnancy, Adult, Drug-Related Side Effects and Adverse Reactions epidemiology, Miconazole adverse effects, Miconazole administration & dosage, Clotrimazole adverse effects, Candidiasis, Vulvovaginal drug therapy, Antifungal Agents adverse effects, Antifungal Agents therapeutic use, Imidazoles adverse effects, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems
- Abstract
Azole antifungal drugs are commonly used to treat vulvovaginal candidiasis (VVC). The nephrotoxicity and developmental toxicity of azole drugs have not been systematically analyzed in the real world. We used the FDA Adverse Event Reporting System (FAERS) to investigate the adverse events (AEs) associated with imidazole therapy for VVC. FAERS data (from quarter 1 2004 to quarter 3 2022) were retrieved using OpenVigil 2.1, and AEs were retrieved and standardized according to the Medical Dictionary for Regulatory Activities (MedDRA). In the top 10 System Organ Class (SOC), all four drugs have been found to have kidney and urinary system diseases and pregnancy. We found significant signals, including clotrimazole [bladder transitional cell carcinoma, (report odds ratio, ROR = 291.66)], [fetal death, (ROR = 10.28)], ketoconazole[nephrogenic anemia (ROR = 22.1)], [premature rupture of membranes (ROR = 22.91 46.45, 11, 3)], Miconazole[hematuria (ROR = 19.03)], [neonatal sepsis (ROR = 123.71)], [spontaneous abortion (ROR = 5.98)], Econazole [acute kidney injury (ROR = 4.41)], [spontaneous abortion (ROR = 19.62)]. We also discovered new adverse reactions that were not reported. Therefore, when using imidazole drugs for treatment, it is necessary to closely monitor the patient's renal function, pay attention to the developmental toxicity of the fetus during pregnancy, and be aware of potential adverse reactions that may occur., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
- Author
-
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, and Ribera JM
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Fusion Proteins, bcr-abl genetics, Philadelphia Chromosome, Progression-Free Survival, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Remission Induction, Adolescent, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Imatinib Mesylate therapeutic use, Imatinib Mesylate adverse effects, Imidazoles therapeutic use, Imidazoles adverse effects, Imidazoles administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Pyridazines therapeutic use, Pyridazines adverse effects
- Abstract
Importance: In newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits BCR::ABL1 and all single-mutation variants, including T315I., Objective: To compare frontline ponatinib vs imatinib in adults with newly diagnosed Ph+ ALL., Design, Setting, and Participants: Global registrational, phase 3, open-label trial in adults aged 18 years or older with newly diagnosed Ph+ ALL. From January 2019 to May 2022, eligible patients at 77 sites were randomized 2:1 to ponatinib (30 mg/d) or imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib or imatinib after the cycle 20 phase of the trial. The last date of follow-up for this analysis was August 12, 2022., Intervention: Patients received ponatinib, 30 mg/d, or imatinib, 600 mg/d, with reduced-intensity chemotherapy, followed by single-agent ponatinib or imatinib after cycle 20. The ponatinib dose was reduced to 15 mg on achievement of minimal residual disease-(MRD) negative complete remission., Main Outcomes and Measures: The primary end point of this interim analysis was MRD-negative complete remission (≤0.01% BCR::ABL1 [MR4] centrally assessed by reverse transcriptase-quantitative polymerase chain reaction), with complete remission maintained for at least 4 weeks at the end of cycle 3. The key secondary end point was event-free survival., Results: Of 245 patients randomized (median age, 54 years; 133 [54.3%] female), 232 (ponatinib, n = 154; imatinib, n = 78) who had p190 or p210 dominant isoforms verified by the central laboratory were analyzed for the primary end point. The MRD-negative complete remission rate (primary end point) was significantly higher with ponatinib (34.4% [53/154]) vs imatinib (16.7% [13/78]) (risk difference, 0.18 [95% CI, 0.06-0.29]; P = .002). At the data cutoff, event-free survival had not met the prespecified number of events. Median event-free survival was not reached in the ponatinib group and was 29 months in the imatinib group. The most common adverse events were similar between treatment groups. Arterial occlusive events were infrequent and comparable between groups (ponatinib, 2.5%; imatinib, 1.2%)., Conclusions and Relevance: Ponatinib demonstrated a superior rate of MRD-negative complete remission at the end of induction vs imatinib when combined with reduced-intensity chemotherapy in adults with newly diagnosed Ph+ ALL. The safety profile of ponatinib was comparable with imatinib., Trial Registration: ClinicalTrials.gov Identifier: NCT03589326.
- Published
- 2024
- Full Text
- View/download PDF
22. Olmesartan Associated Enteropathy as an Inflammatory Bowel Disease Mimicker in a Patient With Hidradenitis Suppurativa.
- Author
-
Melgosa Ramos FJ, García Ruiz R, and Mateu Puchades A
- Subjects
- Humans, Diagnosis, Differential, Female, Male, Angiotensin II Type 1 Receptor Blockers adverse effects, Adult, Hidradenitis Suppurativa chemically induced, Hidradenitis Suppurativa drug therapy, Imidazoles adverse effects, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases complications, Tetrazoles adverse effects
- Published
- 2024
- Full Text
- View/download PDF
23. Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate.
- Author
-
Barthalon E, Dupire G, Calugareanu A, and Said BB
- Subjects
- Humans, Female, Skin Tests, Imidazoles adverse effects, Cross Reactions, Drug Eruptions etiology, Drug Eruptions diagnosis, Aged, Middle Aged, Zoledronic Acid adverse effects, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Pamidronate adverse effects
- Published
- 2024
- Full Text
- View/download PDF
24. Not first-line antihypertensive agents, but still effective-The efficacy and safety of imidazoline receptor agonists: A network meta-analysis.
- Author
-
Érszegi A, Viola R, Bahar MA, Tóth B, Fejes I, Vágvölgyi A, and Csupor D
- Subjects
- Humans, Blood Pressure drug effects, Network Meta-Analysis, Treatment Outcome, Imidazoline Receptors agonists, Antihypertensive Agents therapeutic use, Antihypertensive Agents adverse effects, Hypertension drug therapy, Imidazoles therapeutic use, Imidazoles adverse effects
- Abstract
Cardiovascular disorders are the leading cause of death in the world. Many organ diseases (kidney, heart, and brain) are substantially more prone to develop in people with hypertension. In the treatment of hypertension, first-line medications are recommended, while imidazoline receptor agonists are not first-line antihypertensives. Our goal was to conduct a network meta-analysis to assess the efficacy and safety of imidazoline receptor agonists. The meta-analysis was performed following the PRISMA guidelines using the PICOS format, considering the CONSORT recommendations. Studies were collected from four databases: PubMed, Cochrane Library, Web of Science, and Embase. A total of 5960 articles were found. After filtering, 27 studies remained eligible for network meta-analysis. Moxonidine reduced blood pressure in sitting position statistically significantly after 8 weeks of treatment (SBP MD: 23.80; 95% CI: 17.45-30.15; DBP MD: 10.90; 95% CI: 8.45-13.35) compared to placebo. Moreover, moxonidine reduced blood pressure more effectively than enalapril; however, this difference was not significant (SBP MD: 3.10; 95% CI: -2.60-8.80; DBP MD: 1.30; 95% CI: -1.25-3.85). Dry mouth was experienced as a side effect in the case of all imidazoline receptor agonists. After 8 weeks of treatment, the appearance of dry mouth was highest with clonidine (OR: 9.27 95% CI: 4.70-18.29) and lowest with rilmenidine (OR: 6.46 95% CI: 0.85-49.13) compared to placebo. Somnolence was less frequent with moxonidine compared to rilmenidine (OR: 0.63 95% CI: 0.17-2.31). Imidazoline receptor agonists were nearly as effective as the first-line drugs in the examined studies. However, their utility as antihypertensives is limited due to their side effects. As a result, they are not first-line antihypertensives and should not be used in monotherapy. However, in the case of resistant hypertension, they are a viable option. According to our findings, from the point of view of safety and efficacy, moxonidine appears to be the best choice among imidazoline receptor agonists., (© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
25. More than meets the eye: a scoping review on the non-medical uses of THZ eye drops.
- Author
-
Menshawey E and Menshawey R
- Subjects
- Humans, Adrenergic alpha-Agonists administration & dosage, Ophthalmic Solutions, Imidazoles administration & dosage, Imidazoles adverse effects
- Abstract
Tetrahydrozoline is an alpha agonist imidazole derivative found in over-the-counter decongestive eye and nasal drops. The drug was patented in 1954 and was available for medical use in 1959. This drug recently gained the attention of law enforcement as it has been utilized in criminal activity such as homicide and drug-facilitated sexual assault. The aim of this scoping review is to scope the literature for all mentions of tetrahydrozoline eye/nasal drops use in a non-medical context to delineate areas of future research and development. We used Google Scholar and PUBMED/Medline databases to search for non-medicinal and criminal uses of THZ. The search word used was "tetrahydrozoline." A total of 15 articles matched our criteria. Among the case reports, two (11.1%) cases reported on drug-facilitated sexual assault, and two (11.1%) cases used THZ eyedrops to attempt suicide. Incidental ingestion of THZ eyedrops was reported in eight (44.4%) cases, three (16.7%) cases of attempted murder were reported, two (11.1%) cases of intentional ingestion were reported, and one (5.5%) case was a combination of drug-facilitated sexual assault and attempted murder. The most common clinical presentation was unexplained and resistant bradycardia and hypotension. THZ eye drops can be used to produce false negative results on drug tests. This study recognizes that THZ can be used in non-medicinal and criminal uses. There is room for future research and development. More studies should be conducted to better understand the mechanism of action, therapeutic window, and toxicity levels among various age groups at different methods of intake and to find an effective treatment in case of overdose. Eyedrop and nasal decongestant bottles should be designed with child proofing to prevent incidental ingestion and should contain warning labels. A fast and alternative test to GC/MS can be developed to ease the diagnosis of THZ toxicity. Purchases of this medication may need to be monitored., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Olmesartan induced gastritis and enteropathy.
- Author
-
Gupta A, Jain P, and Gupta L
- Subjects
- Humans, Male, Female, Antihypertensive Agents adverse effects, Angiotensin II Type 1 Receptor Blockers adverse effects, Middle Aged, Gastritis chemically induced, Imidazoles adverse effects, Tetrazoles adverse effects
- Published
- 2024
- Full Text
- View/download PDF
27. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
- Author
-
Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, and Ribas A
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Aged, 80 and over, Molecular Targeted Therapy, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Pyridones administration & dosage, Pyridones adverse effects, Pyrimidinones administration & dosage, Pyrimidinones adverse effects, Pyrimidinones therapeutic use, Imidazoles administration & dosage, Imidazoles therapeutic use, Imidazoles adverse effects, Imidazoles pharmacokinetics, Proto-Oncogene Proteins c-akt metabolism, Oximes administration & dosage, Oximes adverse effects, Oximes therapeutic use, Neoplasms drug therapy, Neoplasms genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Mutation, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: Aberrant PI3K/AKT signaling in BRAF-mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF-mutated solid tumors (ClinicalTrials.gov identifier NCT01902173)., Methods: Patients with BRAF V600E/V600K-mutant solid tumors received oral dabrafenib at 150 mg twice daily with dose escalation of oral uprosertib starting at 50 mg daily, or, in the triplet cohorts, with dose escalation of both oral trametinib starting at 1.5 mg daily and oral uprosertib starting at 25 mg daily. Dose-limiting toxicities (DLTs) were assessed within the first 56 days of treatment. Radiographic responses were assessed at 8-week intervals., Results: Twenty-seven patients (22 evaluable) were enrolled in parallel doublet and triplet cohorts. No DLTs were observed in the doublet cohorts (N = 7). One patient had a DLT at the maximum administered dose of triplet therapy (dabrafenib 150 mg twice daily and trametinib 2 mg daily plus uprosertib 75 mg daily). Three patients in the doublet cohorts had partial responses (including one who had BRAF inhibitor-resistant melanoma). Two patients in the triplet cohorts had a partial response, and one patient had an unconfirmed partial response. Pharmacokinetic data suggested reduced dabrafenib and dabrafenib metabolite exposure in patients who were also exposed to both trametinib and uprosertib, but not in whose who were exposed to uprosertib without trametinib., Conclusions: Concomitant inhibition of both the MAPK and PI3K-AKT pathways for the treatment of BRAF-mutated cancers was well tolerated, leading to objective responses, but higher level drug-drug interactions affected exposure to dabrafenib and its metabolites., (© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
28. Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma.
- Author
-
Ichikawa K, Ohno S, Kubo S, and Nakajima H
- Subjects
- Humans, Female, Aged, Prednisolone therapeutic use, Methotrexate therapeutic use, Methotrexate adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics, Pyridones adverse effects, Pyridones therapeutic use, Pyrimidinones therapeutic use, Pyrimidinones adverse effects, Lung Neoplasms drug therapy, Adenocarcinoma of Lung drug therapy, Imidazoles adverse effects, Imidazoles therapeutic use, Oximes adverse effects, Oximes therapeutic use, Vasculitis chemically induced, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use
- Abstract
The combination therapy of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients with BRAF V600E-positive tumours, including melanoma and lung cancer. Several case reports indicated autoimmune side effects associated with the use of BRAF and MEK inhibitors. Still, the effects of these drugs on the immune system were not fully elucidated. Here, we report a patient with large-vessel vasculitis diagnosed after initiation of treatment with dabrafenib and trametinib for BRAF V600E-positive metastatic lung adenocarcinoma. She was a never-smoker woman in her early 70s who presented with a chronic cough and was diagnosed with BRAF V600E-positive metastatic lung adenocarcinoma by transbronchial lung biopsy. She was successfully treated with prednisolone and methotrexate while BRAF and MEK inhibitors were continued. We should be careful about autoimmune diseases using BRAF and MEK inhibitors., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
29. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
- Author
-
Zhang P, Chen Z, Shi S, Li Z, Ye F, Song L, Zhang Y, Yin F, Zhang X, Xu J, Cheng Y, Su W, Shi M, Fan S, Tan P, Zhong C, Lu M, and Shen L
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Stomach Neoplasms drug therapy, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Esophagogastric Junction pathology, Imidazoles administration & dosage, Imidazoles therapeutic use, Imidazoles adverse effects, Aged, 80 and over, Cohort Studies, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology, Biliary Tract Neoplasms mortality, Esophageal Squamous Cell Carcinoma drug therapy, Esophageal Squamous Cell Carcinoma pathology, Adenocarcinoma drug therapy, Adenocarcinoma pathology, Adenocarcinoma mortality
- Abstract
Background: The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase inhibitor surufatinib showed a tolerable safety profile and preliminary efficacy in patients with advanced solid tumors in a phase I study., Methods: This open-label, multi-cohort study in China enrolled patients with advanced solid tumors who had failed or were intolerable to standard treatment into tumor-specific cohorts. Patients received surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks). Results for three cohorts (gastric/gastroesophageal junction [GC/GEJ] adenocarcinoma, esophageal squamous cell carcinoma [ESCC], and biliary tract carcinoma [BTC]) are reported here. The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation criteria in Solid Tumors version 1.1., Results: Between December 17, 2019, and January 29, 2021, 60 patients were enrolled (GC/GEJ, n = 20; ESCC, n = 20; BTC, n = 20). At data cutoff (February 28, 2023), ORRs were 31.6%, 30.0%, and 11.1%, respectively. Median progression-free survival was 4.1, 2.7, and 2.9 months, respectively. Median overall survival was 13.7, 10.4, and 7.0 months, respectively. Overall, grade ≥ 3 treatment-related adverse events occurred in 28 (46.7%) patients., Conclusions: Surufatinib plus toripalimab showed promising antitumor activity and a tolerable safety profile in immunotherapy-naïve patients with GC/GEJ adenocarcinoma, ESCC, or BTC. These findings warrant further study in larger randomized trials comparing surufatinib plus toripalimab with standard therapies in these tumors., Clinicaltrials: gov NCT04169672., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Chronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: A case report of olmesartan-induced enteropathy.
- Author
-
Sheppard R, Evanson B, Campbell I, and Shand A
- Subjects
- Humans, Female, Middle Aged, Diagnosis, Differential, Angiotensin II Type 1 Receptor Blockers adverse effects, Autoantibodies blood, Protein Glutamine gamma Glutamyltransferase 2, Chronic Disease, Celiac Disease diagnosis, GTP-Binding Proteins immunology, GTP-Binding Proteins antagonists & inhibitors, Imidazoles adverse effects, Diarrhea chemically induced, Tetrazoles adverse effects, Weight Loss, Transglutaminases immunology
- Abstract
Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
31. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial.
- Author
-
Du Y, Yu L, Deng B, Li Q, Hu J, Li L, Xu Y, Song L, Xie F, Wang Y, Chen Y, Liu C, Zhai X, and Lu Y
- Subjects
- Adult, Female, Humans, Male, Young Adult, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents pharmacokinetics, Area Under Curve, China, East Asian People, Healthy Volunteers, Proton Pump Inhibitors adverse effects, Proton Pump Inhibitors pharmacokinetics, Imidazoles adverse effects, Imidazoles pharmacokinetics, Amoxicillin adverse effects, Amoxicillin pharmacokinetics, Bismuth adverse effects, Bismuth pharmacokinetics, Clarithromycin adverse effects, Clarithromycin pharmacokinetics, Drug Interactions, Benzene Derivatives adverse effects, Benzene Derivatives pharmacokinetics
- Abstract
Background: Tegoprazan is a potassium-competitive acid blocker that inhibits gastric acid and which may be used for eradicating Helicobacter pylori. This study focuses on the pharmacokinetic interaction and safety between tegoprazan and the combination of clarithromycin, amoxicillin and bismuth in healthy Chinese subjects., Methods: An open-label, three-period, single-center, multiple-dosage, single-sequence, phase I trial was conducted in 22 healthy subjects. In period 1, the subjects took tegoprazan 50 mg twice daily for 7 days, and in period 2 they were administered clarithromycin 500 mg, amoxicillin 1000 mg and bismuth potassium citrate 600 mg twice daily for 7 days (days 14-20). Tegoprazan, clarithromycin, amoxicillin and bismuth potassium citrate were then administered in combination for 7 days (days 21-27) in period 3. Blood samples were collected up to 12 h after the last dose of each period. Safety assessments were performed in each period., Results: The geometric mean ratios (GMRs) [90% confidence interval (CI)] of maximum plasma concentration at steady state (C
max,ss ) and area under the plasma concentration-time curve over the dosing interval (AUCτ ) at steady state were 195.93% (175.52-218.71%) and 287.54% (263.28-314.04%) for tegoprazan and 423.23% (382.57-468.22%) and 385.61% (354.62-419.30%) for tegoprazan metabolite M1, respectively. The GMRs (90% CI) of Cmax,ss and AUCτ were 83.69% (77.44-90.45%) and 110.30% (102.74-118.41%) for clarithromycin, 126.25% (114.73-138.93%) and 146.94% (135.33-159.55%) for 14-hydroxyclarithromycin, 75.89% (69.73-82.60%) and 94.34% (87.94-101.20%) for amoxicillin, and 158.43% (125.43-200.11%) and 183.63% (156.42-215.58%) for bismuth, respectively. All reported adverse events were mild. The frequency of adverse events during the coadministration stage was not higher than that during the single- or triple-drug administration stages., Conclusion: The plasma exposure of tegoprazan, M1, 14-hydroxyclarithromycin and bismuth was increased after the coadministration of tegoprazan, clarithromycin, amoxicillin and bismuth. The coadministration exhibited favorable safety and tolerability., Clinical Trials Registration: CTR20230643., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2024
- Full Text
- View/download PDF
32. The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.
- Author
-
Habibi MA, Mirjani MS, Ahmadvand MH, Delbari P, and Alasti O
- Subjects
- Humans, Oximes adverse effects, Pyridones adverse effects, Mutation, Antineoplastic Combined Chemotherapy Protocols adverse effects, Imidazoles adverse effects, Glioma drug therapy, Glioma chemically induced, Pyrimidinones
- Abstract
Background: Dabrafenib and trametinib represent targeted therapy options under investigation for treatment of gliomas harboring BRAF V600 mutations. We systematically reviewed the literature and conducted meta-analyses to assess the efficacy and safety of these agents., Methods: PubMed, Embase, and Scopus were searched from inception to September 2023 for studies examining dabrafenib and/or trametinib for gliomas. Outcomes included response rates (ORR, CR, PR), progression rates (PD), 6- and 12-month PFS, adverse events, and dosing modifications. Meta-analyses were conducted using random effect models., Results: Nine studies met the inclusion criteria. Meta-analysis demonstrated overall response rates (ORR) of 50% (95% confidence interval (CI): 35-65%) for low-grade gliomas (LGG) and 40% (95% CI: 29-51%) for high-grade gliomas (HGG). Pooled ORR was 45% (95% CI: 36-54%) for both glioma grades. The complete response rate was 13% (95% CI: 05-27%) for HGG and 5% (95% CI: 1-10%) for both LGG and HGG. Six-month progression-free survival (PFS) rates reached 87% in LGG and 67% in HGG and a pooled 6-month PFS 78% (95% CI: 58-98%), declining at 12 months to 67% and 44%, respectively, with a pooled 12-month PFS 56% (95% CI: 34-79%). Grade 1-4 adverse events occurred in 100% of LGG and 63% of HGG patients., Conclusions: Dabrafenib and trametinib demonstrate promising anti-tumor efficacy in gliomas, particularly low-grade tumors, achieving durable disease stabilization in many patients. However, toxicity significantly limited tolerability. Additional research should further examine efficacy and refine safe administration protocols across glioma subtypes., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
33. Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases.
- Author
-
Kim JW, Jung JY, Kim HA, Son H, and Suh CH
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Administration, Oral, Diphosphonates therapeutic use, Diphosphonates adverse effects, Diphosphonates administration & dosage, Patient Satisfaction, Treatment Outcome, Imidazoles adverse effects, Imidazoles therapeutic use, Imidazoles administration & dosage, Zoledronic Acid therapeutic use, Zoledronic Acid adverse effects, Osteoporosis drug therapy, Osteoporosis chemically induced, Glucocorticoids adverse effects, Glucocorticoids administration & dosage, Glucocorticoids therapeutic use, Bone Density Conservation Agents therapeutic use, Bone Density Conservation Agents adverse effects, Autoimmune Diseases drug therapy, Autoimmune Diseases chemically induced, Patient Preference, Bone Density drug effects
- Abstract
Purpose: We evaluated the preference, patient satisfaction, and efficacy of zoledronic acid compared with oral bisphosphonates (BPs) for glucocorticoid-induced osteoporosis (GIOP) in patients with autoimmune diseases., Methods: We enrolled 50 patients with new fractures or osteoporosis detected on follow-up bone densitometry after at least 1 year of oral BP use among patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of zoledronic acid treatment, patients completed a survey for preference and satisfaction assessment. Treatment efficacy was analysed by comparing bone mineral density changes and fractures with those in a control group of patients who continued oral BP use., Results: Age, sex, treatment duration, and medication history did not differ significantly between the two groups. Among the participants, 86.7% preferred and were more satisfied with intravenous zoledronic acid than with oral BPs, primarily because of the convenience of its administration interval. Only two patients (4%) reported infusion-related adverse events with zoledronic acid. Furthermore, no significant differences were observed in the annualized percentage change in the bone mineral density of the lumbar spine, femur neck, and hip between patients receiving zoledronic acid and those receiving oral BPs. The occurrence of new fractures was consistent across both groups, with two cases in each, showing no significant differences., Conclusion: Patients showed a preference for and greater satisfaction with zoledronic acid, and its efficacy in treating osteoporosis was comparable to that of oral BPs. Therefore, zoledronic acid is a suitable treatment option for GIOP in patients with autoimmune diseases., (© The Author(s) 2024. Published by Oxford University Press on behalf of Fellowship of Postgraduate Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
34. Ponatinib-induced lamellar ichthyosis-like drug eruption.
- Author
-
Byrne N, Forde K, Mcdonald S, Malladi R, and Chan S
- Subjects
- Humans, Female, Antineoplastic Agents adverse effects, Male, Drug Eruptions etiology, Drug Eruptions pathology, Imidazoles adverse effects, Pyridazines adverse effects, Ichthyosis, Lamellar chemically induced, Ichthyosis, Lamellar pathology
- Published
- 2024
- Full Text
- View/download PDF
35. Enteropathy and intestinal malabsorption in patients treated with antihypertensive drugs. A retrospective cohort study .
- Author
-
Lee SR, Lee EG, Cho YH, Park EJ, Lee YI, Choi JI, Kwon RJ, Son SM, Lee SY, Yi YH, Kim GL, Kim YJ, Lee JG, Tak YJ, Lee SH, and Ra YJ
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Intestinal Diseases epidemiology, Adrenergic beta-Antagonists therapeutic use, Adrenergic beta-Antagonists adverse effects, Imidazoles therapeutic use, Imidazoles adverse effects, Tetrazoles therapeutic use, Incidence, Adult, Republic of Korea epidemiology, Cohort Studies, Hypertension drug therapy, Hypertension epidemiology, Malabsorption Syndromes epidemiology, Malabsorption Syndromes complications, Antihypertensive Agents therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Angiotensin Receptor Antagonists adverse effects, Calcium Channel Blockers therapeutic use
- Abstract
Objectives: To investigate differences in the incidence of enteropathy or intestinal malabsorption in patients taking angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), and beta blockers (BBs) at a single center in Korea., Methods: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021., Results: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p =0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p =0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p =0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p =0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities., Conclusion: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs., (Copyright: © Saudi Medical Journal.)
- Published
- 2024
- Full Text
- View/download PDF
36. The aflatoxin B 1 -induced imidazole ring-opened guanine adduct: High mutagenic potential that is minimally affected by sequence context.
- Author
-
Minko IG, Kellum AH Jr, Stone MP, and Lloyd RS
- Subjects
- Animals, Aflatoxin B1 toxicity, DNA Adducts genetics, Guanine, Mutagenesis, Imidazoles adverse effects, Mutagens toxicity, Liver Neoplasms pathology
- Abstract
Dietary exposure to aflatoxin B
1 (AFB1 ) is a recognized risk factor for developing hepatocellular carcinoma. The mutational signature of AFB1 is characterized by high-frequency base substitutions, predominantly G>T transversions, in a limited subset of trinucleotide sequences. The 8,9-dihydro-8-(2,6-diamino-4-oxo-3,4-dihydropyrimid-5-yl-formamido)-9-hydroxyaflatoxin B1 (AFB1 -FapyGua) has been implicated as the primary DNA lesion responsible for AFB1 -induced mutations. This study evaluated the mutagenic potential of AFB1 -FapyGua in four sequence contexts, including hot- and cold-spot sequences as apparent in the mutational signature. Vectors containing site-specific AFB1 -FapyGua lesions were replicated in primate cells and the products of replication were isolated and sequenced. Consistent with the role of AFB1 -FapyGua in AFB1 -induced mutagenesis, AFB1 -FapyGua was highly mutagenic in all four sequence contexts, causing G>T transversions and other base substitutions at frequencies of ~80%-90%. These data suggest that the unique mutational signature of AFB1 is not explained by sequence-dependent fidelity of replication past AFB1 -FapyGua lesions., (© 2023 Environmental Mutagenesis and Genomics Society.)- Published
- 2024
- Full Text
- View/download PDF
37. Deciphering the role of adjuvant therapy in melanoma and its actual benefits.
- Author
-
Fukushima S, Miyashita A, Kimura T, Kuriyama H, Mizuhashi S, Ichigozaki Y, and Masuguchi S
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Imidazoles adverse effects, Mitogen-Activated Protein Kinase Kinases, Melanoma drug therapy, Melanoma genetics, Skin Neoplasms drug therapy, Skin Neoplasms genetics
- Abstract
Numerous clinical trials have demonstrated a significant improvement in recurrence-free survival among melanoma patients receiving high-dose interferon-α, immune checkpoint inhibitors (pembrolizumab, nivolumab), and BRAF/MEK inhibitors (dabrafenib-trametinib). This study aimed to investigate whether these findings hold true in real-world conditions for patients with stage III and IV melanoma. In particular, the study explores the efficacy and side effects of adjuvant therapies, focusing on anti-PD-1 antibodies and BRAF/MEK inhibitors. While clinical trials have shown comparable efficacy, differences in side-effect profiles, especially the persistence of immune-related adverse events with anti-PD-1 antibodies, highlight the need for careful consideration in adjuvant settings. In the absence of established biomarkers for guiding adjuvant therapy decisions, it becomes imperative to transparently communicate the advantages and disadvantages of drug administration to patients. The study also delved into the impact of melanoma subtype and BRAF mutation status on the effectiveness of adjuvant therapy, emphasizing the need for further investigation., (© 2024 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)
- Published
- 2024
- Full Text
- View/download PDF
38. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
- Author
-
Mitchell AP, Nemirovsky D, Mishra Meza A, Chakraborty N, Persaud S, Farooki A, and Morris MJ
- Subjects
- Male, Humans, Aged, United States, Denosumab adverse effects, Diphosphonates adverse effects, Imidazoles adverse effects, Medicare, Zoledronic Acid therapeutic use, Castration, Bone Density Conservation Agents pharmacology, Bone Density Conservation Agents therapeutic use, Bone Neoplasms complications, Bone Neoplasms drug therapy, Prostatic Neoplasms drug therapy, Osteoporosis chemically induced, Osteoporosis drug therapy
- Abstract
Purpose: Bone-modifying agents (BMAs) do not prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not been assessed., Methods: We used linked SEER-Medicare data 2011-2015 to measure the frequency and number of doses of zoledronic acid (ZA) and denosumab received during CSPC (between diagnosis and initiation of metastatic, castration resistant prostate cancer therapy). We estimated excess BMA among patients who received BMA therapy for CSPC and did not have an indication for osteoporosis fracture prevention. We used the Medicare fee schedule for drug prices and peer-reviewed sources to estimate adverse event frequencies and costs., Results: Median CSPC duration was 387 days (IQR, 253-573), during which time 42% of patients received ≥one dose of denosumab (mean doses, 7) and 18% received ≥one dose of ZA (mean doses, 7). Thirty-eight percent of those receiving denosumab and 47% of those receiving ZA had a history of osteoporosis, osteopenia, spine or hip fracture, or hypercalcemia. The estimated, annual excess BMA cost to Medicare was $44,105,041 in US dollars (USD), composed of $43,303,078 USD and $45,512 USD in drug costs for denosumab and ZA, respectively, and $682,865 USD and $75,585 USD in adverse event costs, respectively. In one-way sensitivity analysis, the estimate was most sensitive to denosumab dosing frequency (estimate range, $28,469,237 USD-$98,830,351 USD) and duration of CSPC (estimate range, $36,823,311 USD-$99,015,908 USD)., Conclusion: BMA overuse in CSPC incurs substantial cost to Medicare, largely because of denosumab drug costs. Excess costs may be reduced by greater adherence to guideline-concordant BMA use.
- Published
- 2024
- Full Text
- View/download PDF
39. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
- Author
-
Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, and Lucenteforte E
- Subjects
- Humans, Child, Adolescent, Hepacivirus genetics, Hepacivirus drug effects, Benzimidazoles therapeutic use, Benzimidazoles adverse effects, Child, Preschool, Carbamates therapeutic use, Carbamates adverse effects, Sulfonamides therapeutic use, Sulfonamides adverse effects, Sofosbuvir therapeutic use, Sofosbuvir adverse effects, Heterocyclic Compounds, 4 or More Rings therapeutic use, Heterocyclic Compounds, 4 or More Rings adverse effects, Drug Combinations, Valine analogs & derivatives, Imidazoles therapeutic use, Imidazoles adverse effects, Cyclopropanes therapeutic use, Quinoxalines, Hepatitis C, Chronic drug therapy, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Sustained Virologic Response, Pyrrolidines therapeutic use, Pyrrolidines adverse effects
- Abstract
Background and Aims: We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct-acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)-infected adolescents (12-18 years), older children (6-11 years), and young children (3-5 years). The purpose of this systematic review and meta-analysis was to inform the World Health Organization (WHO) guidelines., Methods: We included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV-infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12 weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS-I tool. Data were pooled using random-effects models, and certainty of the evidence was assessed using the GRADE approach., Results: A total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96-100), 96% (90-100), and 96% (83-100) for GLE/PIB in adolescents, older, and young children, respectively; 95% (90-99), 93% (86-98), and 83% (70-93), for SOF/VEL, respectively; and 100% (97-100) and 100% (94-100) for SOF/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (<1%) but slightly higher in young children (3%)., Conclusions: All three pan-genotypic DAA regimens were highly effective and well-tolerated and are now recommended by the WHO for use in adults, adolescents, and children down to 3 years, which will simplify procurement and supply chain management. The evidence was based largely on single-arm non-randomized controlled studies. Moreover, there were also missing data regarding key variables such as route of HCV acquisition, presence or absence of cirrhosis, or HIV co-infection that precluded evaluation of the impact of these factors on outcomes., Prospero Record: CRD42020146752., (© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
40. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis.
- Author
-
Na HJ, Jeon N, Staatz CE, Han N, and Baek IH
- Subjects
- Humans, Azepines adverse effects, Azepines therapeutic use, Randomized Controlled Trials as Topic, Pyrrolidines adverse effects, Pyrrolidines therapeutic use, Imidazoles adverse effects, Imidazoles therapeutic use, Sleep Paralysis drug therapy, Hallucinations chemically induced, Hallucinations drug therapy, Pyridines, Pyrimidines, Triazoles, Sleep Initiation and Maintenance Disorders drug therapy, Sleep Initiation and Maintenance Disorders chemically induced, Orexin Receptor Antagonists adverse effects, Orexin Receptor Antagonists therapeutic use, Narcolepsy drug therapy
- Abstract
Study Objectives: Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated with these drugs., Methods: Five prominent databases were searched to identify randomized controlled trials (RCTs) on this topic. Primary safety outcomes included treatment-emergent adverse events (TEAEs), treatment-related TEAEs, TEAEs leading to discontinuation, and serious TEAEs. Excessive daytime sleepiness (EDS), sleep paralysis, and hallucinations were categorized as adverse events (AEs)-related narcolepsy-like symptoms., Results: Eleven RCTs with 7703 patients were included. DORAs were associated with a higher risk of TEAEs (risk ratio [RR], 1.09; 95% confidence interval [CI], 1.03 to 1.15) and treatment-related TEAEs (RR, 1.69; 95% CI: 1.49 to 1.92) when compared to placebo. The DORA group exhibited a significantly higher risk of EDS (RR, 2.15; 95% CI: 1.02 to 4.52) and sleep paralysis (RR, 3.40; 95% CI: 1.18 to 9.80) compared to the placebo group., Conclusion: This meta-analysis achieved a comparative evaluation of the clinical safety and tolerability of FDA-approved DORAs for primary insomnia, specifically focusing on AEs-related narcolepsy-like symptoms. This study contributes to understanding the safety profile of FDA-approved DORAs for treating insomnia., (© The Author(s) 2023. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
41. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
- Author
-
Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Baratè C, Scaffidi L, Elena C, Giai V, Scalzulli E, Breccia M, La Nasa G, and Caocci G
- Subjects
- Adult, Humans, Aged, Aged, 80 and over, Imidazoles adverse effects, Pyrimidines therapeutic use, Protein Kinase Inhibitors adverse effects, Cardiovascular Diseases chemically induced, Cardiovascular Diseases epidemiology, Cardiovascular Diseases drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive chemically induced, Pyridazines
- Abstract
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-fatal cardiovascular diseases. It is based on sex, age, smoking habits, systolic blood pressure, non-high-density lipoprotein cholesterol, and European geographical region of cardiovascular risk. The SCORE2/SCORE2-OP algorithm translated more patients (50.2%) to the high-very high cardiovascular risk category than the previous SCORE (25.3%). Patients with a high to very high SCORE2/SCORE2-OP risk showed a significantly higher incidence rate of AOEs (69.2% vs. 46.5%, p < 0.001). The older SCORE was less specific in estimating AOEs in patients classified as low-intermediate risk (69.8 vs. 54.2%). In multivariate analysis, no associations were found between AOEs and gender, age, and type or dose of tyrosine kinase inhibitor. Only the SCORE2/SCORE2-OP risk was confirmed as a significant predictive factor (p = 0.028; hazard ratio = 2.2; 95% confidence interval = 1.1-4.5). Patients with AOEs required, in most cases, imaging diagnostic tests, additional drugs, and sometimes invasive procedures, increasing access to visits and hospital management. This real-life study suggested that the SCORE2 and SCORE2-OP charts could help identify cardiovascular fragility in CML patients providing them with more attention and a proper TKI selection., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
42. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.
- Author
-
Murray M
- Subjects
- Humans, Cytochrome P-450 Enzyme System metabolism, Cytochrome P-450 Enzyme System genetics, Liver Diseases metabolism, Liver Diseases drug therapy, Membrane Transport Proteins metabolism, Membrane Transport Proteins genetics, Hepatitis C drug therapy, Animals, Biotransformation, Indoles pharmacokinetics, Indoles adverse effects, Pyrrolidines pharmacokinetics, Carbamates pharmacokinetics, Antiviral Agents pharmacokinetics, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Drug Interactions, Valine analogs & derivatives, Imidazoles pharmacokinetics, Imidazoles adverse effects, Imidazoles therapeutic use, Imidazoles metabolism, Isoquinolines pharmacokinetics, Isoquinolines therapeutic use, Isoquinolines adverse effects, Benzazepines pharmacokinetics, Benzazepines adverse effects, Sulfonamides pharmacokinetics
- Abstract
Asunaprevir, daclatasvir, and beclabuvir are direct-acting antiviral agents used in the treatment of patients infected with hepatitis C genotype 1b. This article reviews the biotransformation and disposition of these drugs in relation to the safety and efficacy of therapy. CYP3A4 and 3A5 catalyze the oxidative biotransformation of the drugs, while P-glycoprotein mediates their efflux from tissues. Asunaprevir is also a substrate for the influx transporters OATP1B1 and OATP2B1 and the efflux transporter MRP2, while beclabuvir is also a substrate for the efflux transporter BCRP. Liver disease decreases the expression of CYPs and transporters that mediate drug metabolism and disposition. Serum asunaprevir concentrations, but not those of daclatasvir or beclabuvir, are increased in patients with severe liver disease, which may produce toxicity. Pharmacogenomic variation in CYPs and transporters also has the potential to disrupt therapy with asunaprevir, daclatasvir and beclabuvir; some variants are more prevalent in certain racial groups. Pharmacokinetic drug-drug interactions, especially where asunaprevir, daclatasvir, and beclabuvir are victim drugs, are mediated by coadministered rifampicin, ketoconazole and ritonavir, and are attributable to inhibition and/or induction of CYPs and transporters. Conversely, there is also evidence that asunaprevir, daclatasvir and beclabuvir are perpetrators of drug interactions with coadministered rosuvastatin and dextromethorphan. Together, liver disease, pharmacogenomic variation and drug-drug interactions may disrupt therapy with asunaprevir, daclatasvir and beclabuvir due to the impaired function of important CYPs and transporters., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
43. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
- Author
-
Saussele S, La Rosée P, Kiani A, Haverkamp W, Jentsch-Ullrich K, Stegelmann F, Rieger C, Waller CF, Franke GN, Junghanss C, Kirchmair R, Theurl M, and le Coutre P
- Subjects
- Humans, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents administration & dosage, Germany, Consensus, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Practice Guidelines as Topic, Cardiovascular Diseases prevention & control, Pyridazines therapeutic use, Pyridazines adverse effects, Pyridazines administration & dosage, Imidazoles therapeutic use, Imidazoles administration & dosage, Imidazoles adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum., Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice., Key Messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
44. Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study.
- Author
-
Friedland R, Glick M, Amitay-Laish I, and Toledano H
- Subjects
- Humans, Retrospective Studies, Male, Female, Child, Adolescent, Child, Preschool, Pyridones adverse effects, Pyrimidinones adverse effects, Infant, Severity of Illness Index, Imidazoles adverse effects, Oximes adverse effects, Oximes therapeutic use, Benzimidazoles adverse effects, Paronychia chemically induced, Drug Eruptions etiology, Protein Kinase Inhibitors adverse effects, Proto-Oncogene Mas
- Abstract
Introduction: Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors are in use for several indications for adults and children. Cutaneous toxicities are among the most common adverse effects. We aimed to describe the spectrum of cutaneous adverse events, its frequency, and severity in a cohort of pediatric patients., Methods: We reviewed all records of patients in our tertiary treatment center treated with MEK inhibitors between January 2016 and January 2023 for all indications., Results: Among 33 patients, 76% reported cutaneous adverse effects. The highest prevalence was in the group of patients treated with trametinib (90%), followed by the group treated with selumetinib (50%) and the group treated with a combination of trametinib and B-Raf proto-oncogene serine/threonine-protein kinase inhibitor (dabrafenib, 34%). Xerosis, dermatitis, paronychia, and hair heterochromia were most frequently reported. Severity was graded 1 or 2 for most adverse events, and 237 visits to the dermatology clinic related to these adverse events were recorded., Conclusions: Cutaneous adverse events are common in the pediatric population as in adults, but the clinical spectrum is different. Although considered mild, multiple dermatological consultations reflect the distress caused by these events. Dermatologists have a central role in the multidisciplinary care of pediatric patients receiving these agents., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
45. Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis.
- Author
-
Zhang S, Lai H, Chen H, Wang J, Tu H, and Li J
- Subjects
- Humans, Tyrosine Kinase Inhibitors, Pyridazines administration & dosage, Pyridazines adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Imidazoles administration & dosage, Imidazoles adverse effects, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Network Meta-Analysis, Randomized Controlled Trials as Topic, Antineoplastic Agents adverse effects, Antineoplastic Agents administration & dosage, Dose-Response Relationship, Drug
- Abstract
Objective: Ponatinib was recommended with caution because of its high risk of causing arterial occlusion events in chronic myeloid leukemia (CML) patients. The purpose of this study was to understand the efficacy and safety of different doses of ponatinib in the treatment of CML, and to compare it with other tyrosine kinase inhibitors (TKIs)., Method: A network meta-analysis (NMA) was conducted by searching randomized controlled trials (RCTs) of ponatinib in patients with CML to compare the efficacy and safety of ponatinib, and ranked under the cumulative ranking curve (SUCRA) to evaluate the optimal treatment., Results: A total of seven articles with eight RCTs were included in this study, involving 45 mg, 30 mg and 15 mg ponatinib doses. Seven outcome indexes were analyzed. The results showed that 45 mg ponatinib was superior to other doses of ponatinib and other TKIs in CCyR, MCyR and CHR, but the incidence of SAEs and AOEs was significantly higher than other treatment regimens., Conclusion: Ponatinib, with an initial dosage of 45 mg and a gradual reduction to 15 mg, may be a more favorable option for patients with CML at all stages of disease progression, rather than just those in the chronic phase of CML.
- Published
- 2024
- Full Text
- View/download PDF
46. Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study.
- Author
-
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, and Ge J
- Subjects
- Humans, Olmesartan Medoxomil pharmacology, Amlodipine adverse effects, Hydrochlorothiazide therapeutic use, Tetrazoles pharmacology, Imidazoles adverse effects, Drug Therapy, Combination, Double-Blind Method, Antihypertensive Agents adverse effects, Blood Pressure physiology, Essential Hypertension drug therapy, Hypertension drug therapy, Hypertension epidemiology, Hypertension chemically induced, Amlodipine Besylate, Olmesartan Medoxomil Drug Combination, Leukemia, Myeloid, Acute chemically induced, Leukemia, Myeloid, Acute drug therapy, Sulfonamides
- Abstract
There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (±SE) change of SeSBP/SeDBP was -10.8 ± 0.4/-6.6 ± 0.3 mmHg at W4 and -12.7 ± 0.5/-7.6 ± 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension., (© 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
47. [Application of HS221GI in treatment of influenza and ARVI in adults: a new approach - managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial].
- Author
-
Malyavin AG, Bagaeva MI, and Kalyuzhin OV
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Double-Blind Method, Russia, Treatment Outcome, Inflammation drug therapy, Young Adult, Imidazoles administration & dosage, Imidazoles pharmacology, Imidazoles adverse effects, Influenza, Human drug therapy
- Abstract
Aim: Evaluation of the efficacy and safety of the drug Aterixen
® (XC221GI, 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione), in the treatment of uncomplicated forms of influenza and other ARVI in adults., Materials and Methods: The phase III clinical trial enrolled 260 people aged 18-65 years with mild and moderate forms of influenza or other ARVI. Patients were randomly assigned to two groups: in group 1 ( n =130), patients were prescribed the drug Aterixen® in tablets of 100 mg 2 times a day for 5 days; in group 2 ( n =130) - a placebo corresponding to the drug, in the same regimen. The primary endpoint of the efficacy assessment was the time in hours from the first administration of the drug to clinical improvement. The main efficacy analysis was performed in a population of patients with PCR-confirmed influenza or ARVI who completed the study according to the protocol (per protocol infected). Additionally, efficacy was evaluated in ITT and PP populations, including patients with both identified and undetected pathogen. The population for safety analysis included all patients, without exception, who were exposed to at least one exposure to the study drug or placebo., Results: A statistically significant superiority of the drug Aterixen® over placebo in primary endpoint was revealed in both the main and additional analysis in all studied populations: clinical improvement in the group of the studied drug occurred 24 hours faster compared with the placebo group. The evaluation of the effectiveness of secondary endpoints confirmed the superiority of the drug Aterixen® over placebo in terms of relief of catarrhal symptoms and symptoms of intoxication. A favorable safety profile of the drug has been demonstrated., Conclusion: The drug has demonstrated a favorable safety profile for use in outpatient practice. Aterixen® is an effective and safe treatment for influenza and other ARVI in adults.- Published
- 2023
- Full Text
- View/download PDF
48. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
- Author
-
Han Y, Zhou Y, Na J, Li F, and Sun Y
- Subjects
- Humans, Aminobutyrates therapeutic use, Aminobutyrates adverse effects, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin II Type 1 Receptor Blockers adverse effects, Angiotensin Receptor Antagonists therapeutic use, Angiotensin Receptor Antagonists adverse effects, Antihypertensive Agents therapeutic use, Antihypertensive Agents adverse effects, Biphenyl Compounds, Drug Combinations, Treatment Outcome, Blood Pressure drug effects, Hypertension drug therapy, Hypertension physiopathology, Hypertension diagnosis, Imidazoles therapeutic use, Imidazoles adverse effects, Randomized Controlled Trials as Topic, Tetrazoles therapeutic use, Tetrazoles adverse effects, Valsartan therapeutic use, Valsartan adverse effects
- Abstract
Background: Sacubitril/valsartan (LCZ696) is a widely used drug for hypertension in Asia, popular for its efficacy and safety. However, there has been no comprehensive literature review comparing it with olmesartan. This meta-analysis compared the antihypertensive and adverse effects of sacubitril/valsartan and olmesartan., Methods: We conducted a comprehensive search of Pubmed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov databases to identify eligible randomized controlled trials (RCTs). The data were then analyzed and processed using Revman 5.4 and Stata SE14 software., Results: Six RCTs with 4,127 patients were identified, showing that LCZ696 had better blood pressure control than olmesartan; mean sitting systolic and diastolic blood pressure, sitting pulse pressure, 24-hour ambulatory systolic blood pressure, and 24-hour ambulatory diastolic blood pressure were significantly decreased with LCZ696 compared with olmesartan. No significant difference between LCZ696 and olmesartan was observed in the occurrence of the majority of adverse events, with a decreased probability of headache in patients with sacubitril/valsartan compared with olmesartan. The subgroup analysis showed treatment with 400 mg/d LCZ696 was better than olmesartan in reducing serious adverse events., Conclusions: Sacubitril/valsartan was better than olmesartan in controlling blood pressure in patients with hypertension, with relatively higher safety., (© The Author(s) 2023. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
49. Olmesartan-associated sprue-like enteropathy.
- Author
-
Briongos-Figuero LS and Cuevas-González J
- Subjects
- Humans, Imidazoles adverse effects, Tetrazoles adverse effects, Diarrhea chemically induced, Celiac Disease chemically induced, Celiac Disease diagnosis, Intestinal Diseases
- Abstract
Competing Interests: Declaration of interests We declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
50. Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial.
- Author
-
Granild-Jensen JB, Møller-Madsen B, Rackauskaite G, Farholt S, Søndergaard C, Sørensen TH, Vestergaard ET, and Langdahl BL
- Subjects
- Humans, Child, Zoledronic Acid therapeutic use, Bone Density, Diphosphonates therapeutic use, Imidazoles adverse effects, Lumbar Vertebrae diagnostic imaging, Bone Density Conservation Agents adverse effects, Cerebral Palsy drug therapy
- Abstract
Context: Zoledronate appears to reduce fracture rates in children with cerebral palsy (CP), but no previous randomized, controlled trial has been performed to compare the effect of zoledronate to placebo in children with CP., Objective: To investigate the effect of zoledronate on bone mineral density (BMD) Z-scores in children with nonambulant CP in a randomized, controlled, double-blind trial., Methods: Nonambulant children with CP (5 to 16 years of age) were randomized 1:1 to receive 2 doses of zoledronate or placebo at a 6-month interval. BMD Z-score changes at the lumbar spine and the lateral distal femur (LDF) were calculated from dual-energy x-ray absorptiometry scans. Monitoring included weight, bone age, pubertal staging, knee-heel length, adverse events, biochemical markers, and questionnaires., Results: Twenty-four participants were randomized and all completed the study. Fourteen were assigned to zoledronate. The mean lumbar spine BMD Z-score increased 0.8 SD (95% CI: 0.4; 1.2) in the zoledronate group, which was significant when compared to 0.0 SD (95% CI: -0.3; 0.3) in the placebo group. Similarly, the LDF BMD Z-scores increased more in the zoledronate group. Severe acute phase symptoms affected 50% of the patients in the zoledronate group but were reported exclusively after the first dose. Growth parameters were similar in both groups., Conclusion: Zoledronate for 12 months increased BMD Z-scores significantly without affecting growth, but first-dose side effects were common and considerable. Studies into lower first doses and long-term outcomes are needed., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.